TACSTD2 and breast carcinoma: However, HER2-zero tumors may also benefit from ADCs, for example in form of TROP2-targeted agents such as Sacituzumab Govitecan, which is effective in treating metastatic HRpHER2n breast cancer as demonstrated by the TROPiCS-02 trial55.